Yan Yuan Pharmaceuticals and South Korea's NewG Lab jointly developed ROS1/NTRK dual-target inhibitors.

Today (July 16), innovative pharmaceutical research and development company Yu Yuan Pharma announced that it has partnered with NewG Lab Pharma of South Korea to award its next-generation ROS1/NTRK inhibitor talettctinib exclusive to the latter in the Korean market for clinical development and commercializationUnder the agreement, The Pharmaceuticals will receive a $7 million milestone payment and double-digit royalties, and NewG Lab will be responsible for the development and commercialization of talettinib in Korea, while being allowed to participate in the drug's ongoing multi-region 2 clinical trial for non-small cell lung cancer (NSCLC) patients with ROS1/NTRK mutationsTalectctinib is a new, effective, highly selective next-generation ROS1 and NTRK dual-target small molecular inhibitor that crosses the blood-brain barrierThe research project was originally developed by Daiichi Sankyo, which acquired the drug's exclusive global rights in the development, production and commercialization of the drug in December 2018At present, taletrectinib has completed Phase 1 clinical trials in Japan and the United States to treat patients with ROS1 or NTRK fusion gene solid tumors, and Phase 2 clinical trials (NCT04395677) are under wayIn China, the drug was approved in China in March this year for two clinical studies on NSCLC with the ROS1 fusion gene and non-tumor patients with NTRK fusion genesJust last month, a phase 1 clinical data from taletrectinib was published online by Clinical Cancer Research, a oncology journal of the American Association for Cancer Research (AACR)The study, conducted in u.Ssolid tumor patients, showed that taletctinib had controlled toxicity at 800 mg of MTD per day and had observed initial efficacy in patients with CR1-splinter lung cancer (NSCLC), which was resistant to creatic"We are very pleased to have partnered with NewG Lab to launch the development of taletctinib in Korea," said DrWang Yuyuan, CEO and Co-Founder of Yuyuan PharmaThis transaction further strengthens our funding flow and will support accelerating the global development process for the first- and second-line NSCLC patients in the research drug for ROS1/NTRK mutationsWe will rapidly move on to the global development and expansion of our product development pipeline, while continuing to pursue opportunities for other regional or global partnershipsFounded in November 2018, Yuyuan Pharmaceuticals is a clinical biopharmaceutical company that develops new types of oncology therapiesAt the beginning of 2019, the company completed a round of financing of approximately RMB 100 million, with an exclusive investment by Decheng CapitalThe partnership with South Korea's NewG Lab is another milestone for the start-up new drug development companyOriginal title: Joint development of ROS1/NTRK dual-target inhibitors, Yanyuan Pharmaceuticals and South Korea's NewG Lab to reach a cooperation!